<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EPIDUOÂ - adapalene and benzoyl peroxideÂ gelÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use EPIDUO Gel safely and effectively.
See full prescribing information for EPIDUO Gel.
EPIDUO (adapalene and benzoyl peroxide) Gel 0.1%/2.5%
For topical use
Initial U.S. Approval: 2008</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">EPIDUO gel is a combination of adapalene, a retinoid, and benzoyl peroxide, and is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in patients 12 years of age and older. (<a href="#AC007F5A-7CC4-4289-9A76-E1B324F32CFC">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">EPIDUO gel is not for oral, ophthalmic, or intravaginal use. (<a href="#A91560BC-601D-4295-B3E6-2261BE73E8B7">2</a>) <br>Apply a thin film of EPIDUO gel to affected areas of the face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek). Avoid the eyes, lips and mucous membranes.Â (<a href="#A91560BC-601D-4295-B3E6-2261BE73E8B7">2</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Each gram of EPIDUO gel contains 1 mg (0.1%) adapalene and 25 mg (2.5%) benzoyl peroxide.Â (<a href="#AB5E283A-4E66-4D61-8534-0A47FDA81A30">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<a href="#A8D49B30-169D-41B7-84AC-202380B9C379">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">Ultraviolet Light and Environmental Exposure:Â  Avoid exposure to sunlight and sunlamps.Â  Wear sunscreen when sun exposure cannot be avoided. (<a href="#E336D68F-D3EB-4457-8336-573B6DA4E6B2">5.1</a>) </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, scaling, dryness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>/burning, irritant and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> may occur with use of EPIDUO gel and may necessitate discontinuation. (<a href="#E336D68F-D3EB-4457-8336-573B6DA4E6B2">5.2</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most commonly reported adverse events (â‰¥1%) in patients treated with EPIDUO gel were <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">application site burning</span>, <span class="product-label-link" type="condition" conceptid="4318383" conceptname="Application site irritation">application site irritation</span> and <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>.Â (<a href="#A2E65297-5DCB-4676-A405-F9A2A3E9281D">6</a>) </p>
<p class="Highlighta">Â  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact: Galderma Laboratories, L.P. at 1-866-735-4137, or FDA at 1-800-FDA-1088 or go to <span class="Italics">www.fda.gov/medwatch</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Ultraviolet Light and Environmental Exposure</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Local Cutaneous Reactions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AC007F5A-7CC4-4289-9A76-E1B324F32CFC"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">EPIDUO gel is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in patients 12 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="A91560BC-601D-4295-B3E6-2261BE73E8B7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">For topical use only; EPIDUO gel is not for oral, ophthalmic, or intravaginal use.</p>
<p>Apply a thin film of EPIDUO gel to affected areas of the face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek). Avoid the eyes, lips and mucous membranes.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="AB5E283A-4E66-4D61-8534-0A47FDA81A30"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Each gram of EPIDUO gel contains 1 mg (0.1%) adapalene and 25 mg (2.5%) benzoyl peroxide in a white to very <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, opaque, aqueous based gel.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="A8D49B30-169D-41B7-84AC-202380B9C379"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="E336D68F-D3EB-4457-8336-573B6DA4E6B2"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 Ultraviolet Light and Environmental Exposure</h2>
<p class="First">Exposure to sunlight, including sunlamps, should be minimized during the use of EPIDUO gel. Patients with high levels of sun exposure and those with inherent sensitivity to sun should exercise particular caution. Use of sunscreen products and protective apparel, (e.g., hat) are recommended when exposure cannot be avoided. Weather extremes, such as <span class="product-label-link" type="condition" conceptid="4221803" conceptname="Flatus">wind</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, may be irritating to patients under treatment with EPIDUO gel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 Local Cutaneous Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, scaling, dryness, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>/burning may be experienced with use of EPIDUO gel. These are most likely to occur during the first four weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the medication. Irritant and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> may occur. Depending upon the severity of these adverse reactions, patients should be instructed to use a moisturizer, reduce the frequency of the application of EPIDUO gel, or discontinue use. The product should not be applied to cuts, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span>, eczematous or sunburned skin. As with other retinoids, use of "waxing" as a depilatory method should be avoided on skin treated with EPIDUO gel.</p>
<p>Avoid concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have strong skin-drying effect and products with high concentrations of alcohol, astringents, spices, or limes).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="A2E65297-5DCB-4676-A405-F9A2A3E9281D"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>During clinical trials, 1401 subjects were exposed to EPIDUO gel. A total of 1036 subjects with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>, 12 years and older, were treated once daily for 12 weeks to 12 months. Related adverse events reported within 12 weeks of treatment and in at least 1% of subjects treated with EPIDUO gel and those reported in subjects treated with the vehicle gel are presented inÂ Table 1:</p>
<a name="SPLSERV-5E88229E-5162-921F-C1D8-6FA631FCB637"></a><table frame="box" width="80%">
<caption><span>Table 1 Drug Related Adverse Events Reported in Clinical Trials by At Least 1% of Patients Treated For 12 Weeks</span></caption>
<colgroup>
<col width="34%">
<col width="33%">
<col width="33%">
</colgroup>
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">System Organ Class/Preferred Term</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Epiduo gel</span><span class="Bold"><br></span><span class="Bold">N = 564</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Vehicle gel</span><span class="Bold"><br></span><span class="Bold">N = 489</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Subjects with AE(s) </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">14%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">7%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â Â Â  <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">Application site burning</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4318383" conceptname="Application site irritation">Application site irritation</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;1%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin irritation</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0%</td>
</tr>
</tbody>
</table>
<p>Local tolerability evaluations, presented in Table 2, were conducted at each study visit in clinical trials by assessment of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, dryness, burning, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>.</p>
<a name="SPLSERV-525AC54C-9654-B1BA-C01E-D25EFB651769"></a><table frame="box" width="80%">
<caption><span>Table 2 Incidence of Local Cutaneous Irritation in Controlled Clinical Trials (N = 553) Treatment Emergent Signs and Symptoms </span></caption>
<colgroup>
<col width="16%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3">Maximum Severity<br>During Treatment</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3">End of Treatment Severity<br>(12 Weeks)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Mild</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Moderate</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Severe</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Mild</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Moderate</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Severe</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Botrule Lrule Toprule" align="center">27%</td>
<td class="Botrule Lrule Toprule" align="center">13%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
<td class="Botrule Lrule Toprule" align="center">8%</td>
<td class="Botrule Lrule Toprule" align="center">2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Scaling</td>
<td class="Botrule Lrule Toprule" align="center">35%</td>
<td class="Botrule Lrule Toprule" align="center">11%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
<td class="Botrule Lrule Toprule" align="center">9%</td>
<td class="Botrule Lrule Toprule" align="center">1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Dryness</td>
<td class="Botrule Lrule Toprule" align="center">41%</td>
<td class="Botrule Lrule Toprule" align="center">13%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
<td class="Botrule Lrule Toprule" align="center">10%</td>
<td class="Botrule Lrule Toprule" align="center">2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;1%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span>/burning</td>
<td class="Botrule Lrule Toprule" align="center">41%</td>
<td class="Botrule Lrule Toprule" align="center">15%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3%</td>
<td class="Botrule Lrule Toprule" align="center">7%</td>
<td class="Botrule Lrule Toprule" align="center">2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1%</td>
</tr>
</tbody>
</table>
<p>Analysis over the 12-week period showed that local tolerability scores for <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, dryness, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>/burning peaked at Week 1 of therapy and decreased thereafter.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of EPIDUO Gel:Â  <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, sunburn, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, <span class="product-label-link" type="condition" conceptid="4115411" conceptname="Pain of skin">pain of skin</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling face</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span> and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>.Â  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Concomitant topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, desquamating, or abrasive agents.</p>
<p>No formal drug-drug interaction studies were conducted with EPIDUO gel.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C. There are no well-controlled trials in pregnant women treated with EPIDUO gel. Animal reproduction studies have not been conducted with the combination gel or benzoyl peroxide. Furthermore, such studies are not always predictive of human response; therefore, EPIDUO gel should be used during pregnancy only if the potential benefit justifies the risk to the fetus.</p>
<p>No teratogenic effects were observed in rats treated with oral doses of 0.15 to 5.0 mg adapalene/kg/day, up to 25 times (mg/m<span class="Sup">2</span>/day) the maximum recommended human dose (MRHD) of 2 grams of EPIDUO gel. However, teratogenic changes were observed in rats and rabbits when treated with oral doses of â‰¥ 25 mg adapalene/kg/day representing 123 and 246 times MRHD, respectively. Findings included <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, <span class="product-label-link" type="condition" conceptid="432419" conceptname="Encephalocele">encephalocele</span> and skeletal abnormalities in rats; and <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span>, <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">exophthalmos</span> and kidney and skeletal abnormalities in rabbits.</p>
<p>Dermal teratology studies conducted in rats and rabbits at doses of 0.6-6.0 mg adapalene/kg/day [25-59 times (mg/m<span class="Sup">2</span>) the MRHD] exhibited no fetotoxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether adapalene or benzoyl peroxide is excreted in human milk following use of EPIDUO gel.Â  Because many drugs are excreted in human milk, caution should be exercised when EPIDUO gel is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of EPIDUO gel in pediatric patients under the age of 12 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of EPIDUO gel did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">EPIDUO (adapalene and benzoyle peroxide) gel, 0.1%/2.5% is a white to very <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, opaque gel for topical use containing adapalene 0.1% Â and benzoyl peroxide 2.5%.</p>
<p>Adapalene, a synthetic retinoid, is a naphthoic acid derivative with retinoid-like properties.Â  The chemical name for adapalene is (6-[3-(1-adamantyl)-4-methoxyphenyl]-2-Â  naphthoic acid). It has the following structural formula:</p>
<p>Adapalene:</p>
<p><img alt="adapalene structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67002593-3bd3-4e91-a48f-9f7483e579a0&amp;name=epiduo-figure-01.jpg"></p>
<p><span class="Bold">Molecular formula:Â  C<span class="Sub">28</span>H<span class="Sub">28</span>O<span class="Sub">3</span>Â Â Â Â Â Â  Molecular weight: 412.5</span></p>
<p>Benzoyl Peroxide is a highly lipophilic oxidizing agent that localizes in both bacterial and keratinocyte cell membranes.Â  The chemical name for benzoyl peroxide is dibenzoyl peroxide.Â  It has the following structural formula:</p>
<p>Benzoyl Peroxide:</p>
<p><img alt="bp structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67002593-3bd3-4e91-a48f-9f7483e579a0&amp;name=epiduo-figure-02.jpg"></p>
<p><span class="Bold">Molecular formula: C<span class="Sub">14</span>H<span class="Sub">10</span>O<span class="Sub">4</span>Â Â Â Â Â  Molecular weight: 242.23</span></p>
<p>EPIDUO gel contains the following inactive ingredients: acrylamide/sodium acryloyldimethyltaurate copolymer, docusate sodium, edetate disodium, glycerin, isohexadecane, poloxamer 124, polysorbate 80, propylene glycol, purified water, and sorbitan oleate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="Italics">Adapalene </span></p>
<p>Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> is unknown.</p>
<p><span class="Italics">Benzoyl peroxide</span></p>
<p>Benzoyl peroxide is an oxidizing agent with bacteriocidal and keratolytic effects.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Pharmacodynamics of EPIDUO gel is unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">A pharmacokinetic study was conducted in 24 subjects with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> who were treated once daily for 30 days with 2 grams/day of EPIDUO gel applied to 1000 cm<span class="Sup">2</span> of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> involved skin, (face, chest, and upper back).</p>
<p>Two subjects (20%) had quantifiable adapalene plasma concentrations above the limit of quantification (LOQ = 0.1ng/mL). The highest adapalene C<span class="Sub">max</span> and AUC<span class="Sub">0-24h</span> was 0.21 ng/mL and 1.99 ngâ€¢h/mL, respectively. Excretion of adapalene appears to be primarily by the biliary route.</p>
<p>Benzoyl peroxide is absorbed by the skin where it is converted to benzoic acid and eliminated in the urine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity, photocarcinogenicity, genotoxicity, or fertility studies were conducted with EPIDUO gel.</p>
<p>Carcinogenicity studies with adapalene have been conducted in mice at topical doses of 0.4, 1.3, and 4.0 mg/kg/day (1.2, 3.9, and 12 mg/m<span class="Sup">2</span>/day), and in rats at oral doses of 0.15, 0.5, and 1.5 mg/kg/day (0.9, 3.0, and 9.0 mg/m<span class="Sup">2</span>/day).Â  In terms of body surface area, the highest dose levels are 9.8 (mice) and 7.4 times (rats) the MRHD of 2 grams of EPIDUO gel. In the rat study, an increased incidence of benign and malignant pheochromcytomas in the adrenal medulla of male rats was observed.</p>
<p>No significant increase in tumor formation was observed in rodents topically treated with 15-25% benzoyl peroxide carbopol gel (6-10 times the concentration of benzoyl peroxide in EPIDUO gel) for two years. RatsÂ received maximum daily applications of 138 (males) and 205 (females) mg benzoyl peroxide/kg. In terms of body surface area, these levels are 27-40 times the MRHD. Similar results were obtained in mice topically treated with 25% benzoyl peroxide carbopol gel for 56 weeks followed by intermittent treatment with 15% benzoyl peroxide carbopol gel for rest of the 2 years study period, and in mice topically treated with 5% benzoyl peroxide carbopol gel for two years.</p>
<p>The role of benzoyl peroxide as a tumor promoter has been well established in several animal species. However, the significance of this finding in humans is unknown.</p>
<p>In a photocarcinogenicity study conducted with 5% benzoyl peroxide carbopol gel, no increase in UV-induced tumor formation was observed in hairless mice topically treated for 40 weeks.</p>
<p>No photocarcinogenicity studies were conducted with adapalene. However, animal studies have shown an increased tumorigenic risk with the use of pharmacologically similar drugs (e.g., retinoids) when exposed to UV irradiation in the laboratory or sunlight. Although the significance of these findings to humans is not clear, patients should be advised to avoid or minimize exposure to either sunlight or artificial irradiation sources.</p>
<p>Adapalene did not exhibit mutagenic or genotoxic effects <span class="Italics">in vitro</span> (Ames test, Chinese hamster ovary cell assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> TK assay) or <span class="Italics">in vivo</span> (mouse micronucleus test).</p>
<p>Bacterial mutagenicity assays (Ames test) with benzoyl peroxide has provided mixed results, mutagenic potential was observed in a few but not in a majority of investigations. Benzoyl peroxide has been shown to produce single-strand DNA breaks in human bronchial epithelial and mouse epidermal cells, it has caused DNA-protein cross-links in the human cells, and has also induced a dose-dependent increase in sister chromatid exchanges in Chinese hamster ovary cells.</p>
<p>In rat oral studies, 20 mg adapalene/kg/day (120 mg/m<span class="Sup">2</span>/day; 98 times the MRHD based on mg/m<span class="Sup">2</span>/day comparison) did not affect the reproductive performance and fertility of F<span class="Sub">0</span> males and females, or growth, development and reproductive function of F<span class="Sub">1</span> offspring.</p>
<p>No fertility studies were conducted with benzoyl peroxide.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of EPIDUO gel applied once daily for the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> were assessed in two 12-week, multicenter, controlled clinical studies of similar design, comparing EPIDUO gel to the gel vehicle in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> subjects.</p>
<p>Treatment response was defined as the percent of subjects who had a two grade improvement and rated â€˜Clearâ€™ and â€˜Almost Clearâ€™ at Week 12 based on the Investigator's Global Assessment (IGA) and mean absolute change from baseline at Week 12 in both inflammatory and non-inflammatory lesion counts. An IGA score of 'Clear' corresponded to residual hyperpigmentation Â and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> may be present. An IGA score of â€˜Almost Clearâ€™ corresponded to a few scattered comedones and a few small <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>.</p>
<p>In Study 1, 517 subjects were randomized to EPIDUO gel, adapalene 0.1% in vehicle gel, benzoyl peroxide 2.5% in vehicle gel, or vehicle gel. The median age of these 517 subjects was 15 years old and 60% were males. At baseline subjects had between 20 to 50 inflammatory lesions and 30 to 100 non-inflammatory lesions. The majority of subjects had a baseline IGA score of â€˜Moderateâ€™ which corresponded to more than half of the face is involved, many comedones, <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>. The efficacy results at week 12 are presented inÂ Table 3.</p>
<p>In Study 2, 1668 subjects were randomized to EPIDUO gel, adapalene 0.1%Â in vehicle gel, benzoyl peroxide 2.5% in vehicle gel, or vehicle gel. The median age of subjects was 16 years old and 49% were males. At baseline subjects had between 20 to 50 inflammatory lesions and 30 to 100 non-inflammatory lesions as well as an Investigator Global Assessment score of â€˜Moderateâ€™. The efficacy results at week 12 are presented in Table 3.</p>
<a name="SPLSERV-D8A1971E-EB52-FE98-AFB6-CCC2E1A78067"></a><table border="0" frame="box" width="80%">
<caption><span>Table 3: Clinical Efficacy of EPIDUO Gel at Week 12</span></caption>
<thead><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="5" valign="top"><span class="Bold">Study 1</span></td></tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">EPIDUO gel</td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">Adapalene 0.1% in Vehicle gel</td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">Benzoyl Peroxide 2.5% in Vehicle gel</td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">Vehicle gel</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">(N = 149)</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">(N = 148)</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">(N = 149)</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">(N = 71)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">IGA: Two Grade <br>Improvement and <br>Clear or Almost Clear</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">32<br>(21.5%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">18<br>(12.2%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">18<br>(12.1%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4<br>(5.6%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Inflammatory Lesions: <br>Mean Absolute <br>(Percent) Change</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">16.0<br>(52.4%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">11.4<br>(39.9%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10.5<br>(35.8%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">9.5<br>(31.8%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Non-inflammatory <br>Lesions: Mean <br>Absolute (Percent) Change</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">23.4 <br>(45.9%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">15.2<br>(29.6%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">13.7<br>(32.2%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">13.2<br>(27.8%)</td>
</tr>
<tr><td colspan="5">Â </td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="5" valign="top"><span class="Bold">Study 2</span></td></tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">EPIDUO gel</td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">Adapalene 0.1% in Vehicle gel</td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">Benzoyl Peroxide 2.5% in Vehicle gel</td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">Vehicle gel</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">(N = 415)</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">(N = 420)</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">(N = 415)</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">(N = 418)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">IGA: Two Grade <br>Improvement and <br>Clear or Almost Clear</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">125<br>(30.1%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">83<br>(19.8%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">92<br>(22.2%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">47<br>(11.3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Inflammatory Lesions: <br>Mean Absolute <br>(Percent) Change</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">15.4<br>(53.4%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">12.3<br>(41.7%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">13.7<br>(47.6%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8.7<br>(30.2%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Non-inflammatory <br>Lesions: Mean <br>Absolute (Percent) Change</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">24.6<br>(48.1%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">21.0<br>(40.8%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">19.2<br>(37.2%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">11.3<br>(23.2%)</td>
</tr>
</tbody>
</table>
<p>In both Studies 1 and 2 the treatment effect was smaller in subjects with a small number of baseline lesions than in subjects with a large number of baseline lesions.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">EPIDUO (adapalene and benzoyl peroxide) gel 0.1% / 2.5% is white to very <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow in color and opaque in appearance, and is supplied as follows:</p>
<p>45 gram tubeÂ Â Â Â Â Â Â Â  NDC 54868-5991-0<br><br></p>
<p>Storage and handling</p>_<p>Store at 25Âº C; excursions permitted to 15Âº â€“ 30 Âº C (59Âº â€“ 86Âº F).</p>_<p>Protect from light.</p>_<p>Keep out of reach of children.</p>_<p>Keep away from heat.</p>_<p>Keep tube tightly closed.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[See FDA Approved Patient Labeling (Patient Information)]</span></p>
<p>Information for Patients</p>_  <p>Advise patients to cleanse the area to be treated with a mild or soapless cleanser; pat dry. Apply EPIDUO gel as a thin layer, avoiding the eyes, lips and mucous membranes.</p>_  <p>Advise patients not to use more than the recommended amount and not to apply more than once daily as this will not produce faster results, but may increase irritation.</p>_  <p>EPIDUO gel may cause irritation such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, scaling, dryness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> or burning.</p>_  <p>Advise patients to minimize exposure to sunlight, including sunlamps. <br>Recommend the use of sunscreen products and protective apparel, (e.g., hat) when exposure cannot be avoided.</p>_  <p>EPIDUO gel may bleach hair and colored fabric.</p>
<p>Patient Information <br>EPIDUOÂ® (Ep-E-Do-Oh) <br>(adapalene and benzoyl peroxide) <br>gel 0.1%/2.5%</p>
<p><span class="Bold">Important:Â  </span>For use on the skin only (topical).Â  Do not use EPIDUO gel in or on your mouth, eyes, or vagina.</p>
<p>Read this Patient Information leaflet about EPIDUO gel before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your treatment or your medical condition. If you have any questions about EPIDUO gel, talk with your doctor or pharmacist.</p>
<p><span class="Bold">What is EPIDUO gel?</span><br>EPIDUO gel is a prescription medicine for skin use only (topical) used to treat <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in people 12 years of age and older.</p>
<p><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne vulgaris</span> is a condition in which the skin has blackheads, whiteheads and pimples.</p>
<p>It is not known if EPIDUO gel is safe and effective in children younger than 12 years old.</p>
<p><span class="Bold">What should I tell my doctor before using EPIDUO gel?</span><br>Before you use EPIDUO gel, tell your doctor if you:</p>
<ul>
<li>have other skin problems, including cuts or sunburn  </li>
<li>have any other medical conditions  </li>
<li>are pregnant or planning to become pregnant.Â  It is not known if EPIDUO gel can harm your unborn baby.Â  Talk to your doctor if you are pregnant or plan to become pregnant.  </li>
<li>are breastfeeding or plan to breastfeed.Â  It is not known if EPIDUO gel passes into your breast milk and if it can harm your baby.Â  Talk to your doctor about the best way to feed your baby if you use EPIDUO gel.Â  </li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins and herbal supplements.</p>
<p>Especially tell your doctor if you use any other medicine for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.Â  Using EPIDUO gel with topical medicines that contain sulfur, resorcinol or salicylic acid may cause <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>.</p>
<p>Know the medicines you take.Â  Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use EPIDUO gel?</span>.</p>
<ul>
<li>Use EPIDUO gel exactly as your doctor tells you to use it.Â  EPIDUO gel is for skin use only.Â  Do not use EPIDUO gel in or on your mouth, eyes, or vagina. </li>
<li>Apply EPIDUO gel 1 time a day.</li>
<li>Do not use more EPIDUO gel than you need to cover the treatment area.Â  Using too much EPIDUO gel or using it more than 1 time a day may increase your chance of <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>.</li>
</ul>
<p><span class="Bold">Applying EPIDUO gel:</span></p>
<ul>
<li>Wash the area where the gel will be applied with a mild cleanser and pat dry.  </li>
<li>EPIDUO gel comes in a tube and a pump.Â  If you have been prescribed the:  <ul>
<li>Tube:Â Â Squeeze a small amount (about the size of a pea) of EPIDUO gel onto your fingertips and spread a thin layer over the affected area.  </li>
<li>Pump:Â Depress the pump to dispense a small amount (about the size of a pea) of EPIDUO gel and spread a thin layer over the affected area. </li>
</ul>
</li>
</ul>
<p><span class="Bold">What should I avoid while using EPIDUO gel?</span></p>
<ul>
<li>You should avoid spending time in sunlight or artificial sunlight, such as tanning beds or sunlamps. EPIDUO gel can make your skin sensitive to sun and the light from tanning beds and sunlamps.Â  You should wear sunscreen and wear a hat and clothes that cover the areas treated with EPIDUO gel if you have to be in sunlight.  </li>
<li>You should avoid weather extremes such as <span class="product-label-link" type="condition" conceptid="4221803" conceptname="Flatus">wind</span> and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> as this may cause irritation to your skin.  </li>
<li>You should avoid applying EPIDUO gel to cuts, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span> and sunburned skin.  </li>
<li>You should avoid skin products that may dry or irritate your skin such as harsh soaps, astringents, cosmetics that have strong skin drying effects and products containing high levels of alcohol.  </li>
<li>You should avoid the use of â€œwaxingâ€? as a hair removal method on skin treated with EPIDUO gel.  </li>
<li>EPIDUO gel may bleach your clothes or hair.Â  Allow EPIDUO gel to dry completely before dressing to prevent bleaching of your clothes. </li>
</ul>
<p><span class="Bold">What are the possible side effects of EPIDUO gel?<br></span>EPIDUO gel may cause serious side effects including:</p>
<ul>
<li>Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.Â  Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> are most likely to happen during the first 4 weeks of treatment and usually lessen with continued use of EPIDUO gel.Â  Signs and symptoms of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> include: </li>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Redness</span></li>
<li>Dryness</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></li>
<li>Scaling</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span> or burning</li>
</ul>
<p>Tell your doctor right away if these side effects continue for longer than 4 weeks or get worse, you may have to stop using EPIDUO gel.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of EPIDUO gel.Â  For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects.Â  You may report side effects to FDA at 1-800-FDA-1088. </p>
<p>You may also report side effects to GALDERMA LABORATORIES, L.P. at 1-866-735-4137</p>
<p><span class="Bold">How should I store EPIDUO gel?</span></p>
<ul>
<li>Store EPIDUO gel at room temperature, 68Â° â€“ 77Â° F (20Â° â€“ 25Â° C)  </li>
<li>Keep EPIDUO gel inside container and out of light and away from heat.</li>
</ul>
<p><span class="Bold">Keep EPIDUO gel and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about EPIDUO gel<br></span>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use EPIDUO gel for a condition for which it was not prescribed. Do not give EPIDUO gel to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about EPIDUO gel. If you would like more information, talk with your doctor. You can also ask your doctor or pharmacist for information about EPIDUO gel that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in EPIDUO gel?</span><br>Active ingredient: adapalene and benzoyl peroxide<br>Inactive ingredients: acrylamide/sodium acryloydimethyltaurate copolymer, docusate sodium, edetate disodium, glycerin, isohexadecane, polaxamer 124, polysorbate 80, propylene glycol, purified water and sorbitan oleate</p>
<p>Revised:Â  June 2011</p>
<p>Marketed by:<br>GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA<br>Manufactured by:<br>G Production Inc., Baie dâ€™UrfÃ©, QC, H9X 3S4 Canada<br>Made in Canada.<br>GALDERMA is a registered trademark.<br>P51740-0</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OklahomaÂ Â Â Â Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PACKAGE LABEL</h1>
<p class="First"></p>
<p></p>
<p><img alt="epiduo tube label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67002593-3bd3-4e91-a48f-9f7483e579a0&amp;name=5991.jpg"></p>
<p><span class="Bold">NDC 54868-5991-0<br></span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Epiduoâ„¢<br></span>(adapalene and benzoyl peroxide) Gel 0.1% / 2.5%</p>
<p>FOR TOPICAL USE ONLY</p>
<p>NET WT. 45 g</p>
<p><span class="Bold">GALDERMA</span></p>
<p><span class="Bold">For topical use only. Not for ophthalmic, oral or intravaginal use.</span></p>
<p><span class="Bold">Usual dosage:</span> Apply a thin film once a day to affected areas. See package insert for complete prescribing information.</p>
<p><span class="Bold">Each gram contains:</span> adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous gel consisting of acrylamide/sodium acryloyldimethyltaurate copolymer, docusage sodium, edetate disodium, glycerin, isohexadecane, poloxamer 124, polysorbate 80, propylene glycol, purified water, and sorbitan oleate.<br></p>
<p><span class="Bold">Storage:</span> Store at controlled room temperature 68Â°-77Â°F (20Â°-25Â°C) with excursions permitted between 59Â°-86Â°F (15Â°-30Â°C).</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EPIDUOÂ 		
					</strong><br><span class="contentTableReg">adapalene and benzoyl peroxide gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5991(NDC:0299-5908)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ADAPALENE</strong> (ADAPALENE) </td>
<td class="formItem">ADAPALENE</td>
<td class="formItem">1Â mg Â inÂ 1Â g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BENZOYL PEROXIDE</strong> (BENZOYL PEROXIDE) </td>
<td class="formItem">BENZOYL PEROXIDE</td>
<td class="formItem">25Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>docusate sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Isohexadecane</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>poloxamer 124</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sorbitan Monooleate</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5991-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">45 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022320</td>
<td class="formItem">02/24/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8a342236-6044-4c69-ae35-48b4e5338fed</div>
<div>Set id: 67002593-3bd3-4e91-a48f-9f7483e579a0</div>
<div>Version: 2</div>
<div>Effective Time: 20120207</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
